Affiliation:
1. Bayer Pharma AG, 13353 Berlin, Germany
2. Bayer Pharma AG, 42096 Wuppertal, Germany
Abstract
Aim: This study aims to investigate the effect of a transdermal contraceptive patch containing ethinyl estradiol and gestodene on endometrial proliferation over 1 year. Materials & methods: In this open-label, uncontrolled, Phase IIb study, women (aged 18–35 years) used the patch for 13 cycles of 28 days. The primary variable was histologic endometrial effects at cycle 13. Secondary objectives included contraceptive efficacy and safety. Results: Overall, 89 women were treated. At all visits, endometrial biopsies were devoid of any abnormalities. One woman became pregnant. The patch was well tolerated, with no safety concerns. Conclusion: The ethinyl estradiol and gestodene patch had an endometrial effect consistent with suppression of endometrial proliferation in most patients. No endometrial abnormalities or other concerns were reported; compliance was good.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Non-oral routes, novel formulations and devices of contraceptives: An update;Journal of Controlled Release;2022-05
2. Current Progresses and Trends in the Development of Progesterone Receptor Modulators;Current Medicinal Chemistry;2016-08-23
3. A two-centre, open-label, randomised study of ovulation inhibition with three transdermal contraceptive patches, each containing different amounts of ethinyl estradiol and gestodene in healthy, young women;Journal of Obstetrics and Gynaecology;2015-09-30
4. Pharmacokinetics and adhesion of a transdermal patch containing ethinyl estradiol and gestodene under conditions of heat, humidity, and exercise: A single-center, open-label, randomized, crossover study;Clinical Pharmacology in Drug Development;2015-05-08
5. Transdermal contraception methods: today’s patches and new options on the horizon;Expert Opinion on Pharmacotherapy;2015-03-24